VIM-AS1 Promotes Proliferation and Drives Enzalutamide Resistance in Prostate Cancer via IGF2BP2-Mediated HMGCS1 mRNA Stabilization

Gain‑and‑loss experiments were used to investigate the effects of VIM‑AS, a cancer‑specific long non‑coding RNA, on the proliferation and anti‑androgen therapy of LNCaP and C4‑2 cells.